Articles

AACR 2017 Preview: Trying to focus on everything

The AACR annual meeting can’t cover everything, but it may be as close as you can get in one place this year
Written byJeffrey Bouley
| 11 min read

AACR Show Coverage sponsored by Bio-Rad

American Association for Cancer Research (AACR)

AACR Annual Meeting 2017

April 1-5, 2017

Walter E. Washington Convention Center

Washington, D.C.

Trying to focus on everything

The AACR annual meeting can’t cover everything, but it may be as close as you can get in one place this year

WASHINGTON, D.C.—As is pretty much always the case with DDNews show previews such as these, you might be reading this after you’ve decided to go to the annual meeting of the American Association for Cancer Research (AACR) this year, in which case it’s your sneak-peek; you may be reading it while still trying to decide whether to register a bit late, in which case this preview may help tilt the scales for your decision; or you may read it at a point when it’s too late to attend, in which case you might get a sense of why you should strongly consider doing so next year.

And, you may get this issue before you head to the gathering (again, sneak-peek) or you may grab a copy at the show itself, in which case this might help you focus your planning for where to go and when to do it while you’re there at the AACR Annual Meeting 2017.

But, whichever of the above scenarios fits you, we always want there to be a “voice” in these show previews—we want not simply to recycle what’s on the annual meeting website but to give you human guidance. And about the only way to do that is to talk to the people who put together the event. Sometimes it’s a chorus of voices; sometimes a single representative.

This time, it’s Dr. Kornelia Polyak, the program committee chair for the AACR Annual Meeting 2017 and, in her day-to-day life, a professor of medicine at Harvard Medical School and a professor of medicine in the Department of Medical Oncology at the Dana-Farber Cancer Institute.

DDNews: What are the highlights of the annual meeting that you would really like to mention and why?

Dr. Kornelia Polyak: The theme of the meeting is “Research Propelling Cancer Prevention and Cures.” This title and the design of plenary and other major sessions highlights the need to focus on all major areas of cancer research: risk prediction and prevention, early detection, cancer therapies and delivering/accessing care. In general, more emphasis has been placed on cancer treatment, especially treatment of advanced-stage disease due to the urgency of the issue for saving lives. But, we know that preventing cancer and early detection actually have bigger impact on cancer mortality and morbidity than treating advanced disease. Thus, we have to make progress in all areas.

We will have major emphasis on immunology and immunotherapies, precision medicine for both treatment and prevention and also novel technologies such as CRISPR, liquid biospies and single-cell methods (genome-wide profiling and also imaging in situ)—these methods impact all areas of cancer research.

DDNews: What might be of particular interest at the conference for people in the drug discovery and development arena (discovery through clinical trials) and the diagnostics R&D arena (those being the areas most of our readers are in)? Why do those items stand out for you?

Polyak: There will be two “New Drugs on the Horizon” sessions that will be held back to back on Sunday, April 2. We will also have four clinical trials plenary sessions and three clinical trials minisymposia that are developed from submitted abstracts.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.
3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.
3D illustration of a multicolored protein structure composed of folded ribbon-like strands against a blue and teal background with scattered spherical particles
Learn how advanced analytical methods support the characterization of antibody–C1q interactions and the qualification of analytical binding assays.